ExpreS2ion vill testa ES2B-C001 tillsammans med antikroppskonjugat

ExpreS2ion Biotech har ansökt om att ändra protokollet för sin fas I-studie av bröstcancervaccinet ES2B-C001 för att testa det...

13 maj, 2025

Ännu ett lyckat Summit – se alla videos här

Den 20-21 november bjöd vi för sjunde gången in till BioStock Life Science Summit och nu kan du se...

22 november, 2024
BioStock meets industry experts at BIO-Europe

BioStock träffar branschexperter på BIO-Europe

Partneringeventet BIO-Europe har varit ett viktigt nav för life science-branschens aktörer, både för kunskapsutbyte och nätverkande i tre decennier....

5 november, 2024
Bent U Frandsen, CEO of Expres2ion Biotech at BIO-Europe

ExpreS2ion CEO talking about partnering efforts at BIO-Europe

Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also,...

5 november, 2024

Investing in life science: From Seed to Success 2024

Förra veckan samlades investerare och entreprenörer på World Trade Center i Stockholm för "Investing in Life Science: From Seed...

16 september, 2024
Expres2ion to raise SEK 60 million

Rights issue takes Expres2ion breast cancer vaccine to phase I

Having validated its vaccine platform in Covid-19, Expres2ion Biotech now turns to the treatment of breast cancer. A SEK...

14 juni, 2024
Bent U. Frandsen, CEO ExpreS2ion Biotechnologies

ExpreS2ion CEO: “Compelling preclinical package gives us confidence”

Based on its proprietary protein expression platform, ExpreS2ion Biotech advances its ES2B-C001 breast cancer vaccine candidate toward clinical studies....

12 juni, 2024

BioStock Global Forum 2024

On May 29-30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing...

3 juni, 2024
Nyhetssvepet måndag 19 maj

Nyhetssvepet onsdag 5 april

Det senaste från BioStock

5 april, 2023
Bent U. Frandsen, CEO ExpreS2ion Biotech talks about the development and the rights issue

ExpreS2ion CEO comments ongoing rights issue

ExpreS2ion Biotechnologies has a broad portfolio of vaccine candidates based on its ExpreS2 platform. Right now, the company is...

5 april, 2023
Bent U. Frandsen, CEO ExpreS2ion Biotechnologies

BioStock Investor Pitch: ExpreS2ion Biotechnologies

Danish ExpreS2ion Biotechnologies develops a portfolio of vaccines currently targeting Covid-19, breast cancer, influenza, malaria and, with the latest...

3 april, 2023
ExpreS2ion Biotech is looking forward to multiple milestones

Multiple near-term milestones for ExpreS2ion Biotechnologies

With an upcoming phase III readout and ongoing toxicology studies it is safe to say that ExpreS2ion Biotechnologies has...

31 mars, 2023